The SALUT Servei (IBSALUT) has authorized this Friday the processing of a framework agreement to acquire monitors and sensors for patients with diabetes that detect glucose at the subcutaneous level.
As reported on Friday the spokeswoman of the Government, Pilar Costa, at a press conference the supply contract plans to "benefit 525 patients the first year with the acquisition of 6,000 sensors", in addition to all the necessary material for the complete infusionof the continuous insulin pump and the necessary injection ports.
The bidding budget is 3.2 million euros for two years, with an estimated value of the contract of 6.5 million euros.
These devices, on the one hand, continually measure glucose in the interstitial fluid (the space between the cells) by means of an implanted or inserted sensor inside the skin.
With this system it is possible to supervise blood glucose, reduce the number of hospital income due to decompensations and also better control the night episodes of hypoglycemia.
In short, some patients with diabetes are facilitated an adequate control of their disease, so that it improves their quality of life.